A still-developing Canadian COVID-19 vaccine that is delivered by inhaled aerosol rather than an injection is set to enter Phase 2 of human clinical trials at the University of McMaster in Hamilton, Ontario. Researchers at the university are receiving over $8 million in funding from the Canadian Institutes for Health Research (CIHR) to proceed with the new phase…